Printer Friendly
The Free Library
22,719,120 articles and books

Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis.

GAITHERSBURG, Md. -- Oscient Pharmaceuticals has announced the results of yesterday's meeting of the U.S. Food and Drug Administration's (FDA FDA
Food and Drug Administration

FDA, See Food and Drug Administration.

FDA, the abbreviation for the Food and Drug Administration.
) Anti-Infective Drugs Advisory Committee. The panel voted on topics related to the Company's pending supplemental New Drug Application (sNDA) seeking approval for the use of FACTIVE Fac´tive

a. 1. Making; having power to make.
(R) (gemifloxacin mesylate) tablets in treating acute bacterial sinusitis (ABS).

The panel voted on two topics related to the Company's sNDA for ABS. For the first question, the panel voted 10 to 4 that the data from the non-inferiority clinical trials of FACTIVE in ABS were not sufficient to demonstrate efficacy in the treatment of ABS. For the question "Do the safety and effectiveness data presented demonstrate an acceptable risk/benefit profile of FACTIVE (gemifloxacin mesylate) for the 5-day treatment of patients with acute bacterial sinusitis," the panel voted 11 to 2 that the data did not support the approval of FACTIVE for the treatment of ABS.

"We believe strongly that we produced a comprehensive presentation that explicitly detailed the evidence supporting the use of FACTIVE for ABS and would like to recognize the contributions of our employees, consultants and opinion leaders at yesterday's meeting," stated Steven M. Rauscher, President and Chief Executive Officer. "We were pleased to have had the opportunity to present our data and analyses related to the safety and effectiveness of FACTIVE in the treatment of ABS."

The ABS sNDA seeks approval for the treatment of this infection with FACTIVE in a five-day treatment regimen. The sNDA contains data from five Phase III trials involving more than 1,800 patients receiving FACTIVE and 500 patients receiving a comparator. Of the 1,800 patients in the studies, more than 1,100 received FACTIVE for five days of treatment. The filing also includes safety data gathered from the post-marketing surveillance of FACTIVE since launch in September 2004 for the treatment of mild to moderate community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. An FDA decision on this sNDA is expected by December 15, 2006. Although the FDA is not obligated ob·li·gate  
tr.v. ob·li·gat·ed, ob·li·gat·ing, ob·li·gates
1. To bind, compel, or constrain by a social, legal, or moral tie. See Synonyms at force.

2. To cause to be grateful or indebted; oblige.
 to follow the recommendations of the Advisory Committee, it typically does.

Separately, an sNDA for the potential five-day treatment of CAP of mild to moderate severity by FACTIVE is pending and the FDA has set an action date of September 21, 2006 for that application. FACTIVE is currently approved for the seven-day treatment of mild to moderate community-acquired pneumonia and the five-day treatment of acute bacterial exacerbations of chronic bronchitis.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity and ANTARA(R) 130 mg (fenofibrate) capsules, FDA-approved for the adjunct treatment of hypercholesterolemia Hypercholesterolemia Definition

Hypercholesterolemia refers to levels of cholesterol in the blood that are higher than normal.

Cholesterol circulates in the blood stream. It is an essential molecule for the human body.
 (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. Oscient has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium clostridium

Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen.
 difficile-associated disease (CDAD CDAD Clostridium Difficile-Associated Diarrhea
CDAD Component Data Administrator

Important Safety Information about FACTIVE Tablets

The most common (more than 2% incidence) drug-related side effects reported in FACTIVE clinical trials were diarrhea (3.6%), rash (2.8%) and nausea (2.7%). In clinical trials, drug-related rash was reported in 2.8% of patients receiving gemifloxacin and was more commonly observed in patients less than 40 years of age, especially females. The incidence of rash increases with treatment longer than the maximum-labeled duration of 7 days. In clinical trials, the discontinuation rate due to drug-related adverse events was similar for FACTIVE tablets and comparators (2.2% versus 2.1%, respectively).

Gemifloxacin is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone fluoroquinolone /flu·o·ro·quin·o·lone/ (-kwin´o-lon) any of a subgroup of fluorine-substituted quinolones, having a broader spectrum of activity than nalidixic acid.

 antibiotic agents, or any of the product components. Patients receiving marketed fluoroquinolones have reported serious and occasionally fatal hypersensitivity and/or anaphylactic anaphylactic /ana·phy·lac·tic/ (an?ah-fi-lak´tik) pertaining to anaphylaxis.
anaphylactic (an´
 reactions, peripheral neuropathy, antibiotic-associated colitis and tendon ruptures. Gemifloxacin should be discontinued immediately at the first sign of any of these events.

Fluoroquinolones may prolong the QT interval in some patients. Gemifloxacin should be avoided in patients with a history of prolongation of the QTc interval, patients with uncorrected electrolyte disorders (hypokalemia Hypokalemia Definition

Hypokalemia is a condition of below normal levels of potassium in the blood serum. Potassium, a necessary electrolyte, facilitates nerve impulse conduction and the contraction of skeletal and smooth muscles, including the heart.
 or hypomagnesemia hypomagnesemia /hy·po·mag·ne·se·mia/ (-mag?nes-em´e-ah) abnormally low magnesium content of the blood.

An abnormally low level of magnesium in the blood.
), and patients receiving Class IA or Class III antiarrhythmic agents. In clinical studies with gemifloxacin, CNS See Continuous net settlement.


See continuous net settlement (CNS).
 effects have been reported infrequently. As with other fluoroquinolones, gemifloxacin should be used with caution in patients with known or suspected CNS diseases. If CNS reactions occur, gemifloxacin should be discontinued and appropriate measures instituted.

No significant drug-drug interactions were seen with theophylline theophylline /the·oph·yl·line/ (the-of´i-lin) a xanthine derivative found in tea leaves and prepared synthetically; its salts and derivatives act as smooth muscle relaxants, central nervous system and cardiac muscle stimulants, and , digoxin digoxin: see digitalis. , oral contraceptives, cimetidine cimetidine /ci·met·i·dine/ (si-met´i-den) a histamine H2 receptor antagonist, which inhibits gastric acid secretion; used as the base or the monohydrochloride salt in the treatment and prophylaxis of gastric or duodenal ulcers, , omeprazole, and warfarin warfarin (wôr`fərĭn), anticoagulant used to treat blood clots. In large doses it causes bleeding. Warfarin, mixed with bait, is used in rodent control.

Anticoagulant drug, marketed as Coumadin.
, although patients receiving a fluoroquinolone concomitantly with warfarin should be monitored closely. Drug-drug interactions include probenicid, sucralfate sucralfate /su·cral·fate/ (soo-kral´fat) a complex of aluminum and a sulfated polysaccharide, used as a gastrointestinal antiulcerative.

, antacids Antacids Definition

Antacids are medicines that neutralize stomach acid.

Antacids are used to relieve acid indigestion, upset stomach, sour stomach, and heartburn.
 containing aluminum or magnesium, iron, multivitamins containing metal cations, and didanosine didanosine /di·dan·o·sine/ (-dan´o-sen) 2, an analogue of dideoxyadenosine; an antiretroviral agent used for the treatment of advanced HIV-1 infection and acquired immunodeficiency syndrome, administered orally. . The safety and effectiveness of gemifloxacin in children, adolescents (less than 18 years of age), pregnant women, and lactating lac·tate 1  
intr.v. lac·tat·ed, lac·tat·ing, lac·tates
To secrete or produce milk.

[Latin lact
 women have not been established. For complete safety and efficacy information, please see the full prescribing information available at

Forward-Looking Statement

This news release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 including statements related to FDA's anticipated decision on our sNDA seeking approval for the use of FACTIVE tablets in treating ABS. Forward-looking statements represent our management's judgment regarding future events. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "intend," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. We do not plan to update these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of risks affecting our business. For example, our ability to increase our revenue and accelerate the time of our profitability may be limited by: (i) our ability to successfully commercialize and market ANTARA or FACTIVE: the limitations on our resources and experience in the commercialization of products; lack of acceptance by physicians, patients and third party payors; unanticipated safety, product liability, efficacy, or other regulatory issues; delays in recruiting and training sales personnel; problems relating to manufacturing or supply; inadequate distribution of the products by wholesalers, pharmacies, hospitals and other customers; and competition from other products; (ii) by our ability to integrate ANTARA into our business; (iii) whether we will be able to expand the indications for which FACTIVE is approved; (iv) the delay or inability to find sublicensing partners for FACTIVE or to negotiate favorable licensing terms; (v) the delay in or inability to obtain additional regulatory approvals of our products and product candidates due to negative, inconclusive or insufficient results in ongoing or future clinical trials, the FDA requiring additional information or data, delays in the progress of ongoing clinical trials, safety concerns arising with respect to our products or product candidates and disputes with the third parties from whom we license our products or product candidate; and (vi) delays by the FDA. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2006 and in other filings that we may make with the Securities and Exchange Commission from time to time.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 13, 2006
Previous Article:Arbitron Inc. to Present at CL King Best Ideas Conference.
Next Article:U.S. Army Awards 10-Year Contract for Desktop and Mobile Computing to Integration Technologies Group; ITG Cites Commitment to Quality as Success...

Related Articles
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26.
Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis.
Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent.
Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory Committee to Address sNDA for Five-Day Treatment of Acute Bacterial Sinusitis with...
Oscient Pharmaceuticals and Auxilium Pharmaceuticals Agree to Conclude TESTIM(R) Co-Promotion Partnership.
Oscient Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss FACTIVE(R) sNDA for Acute Bacterial Sinusitis.
Oscient Pharmaceuticals Provides Preliminary Revenue Results for Third Quarter 2006.
Oscient Pharmaceuticals Reports Financial Results for Third Quarter of 2006.
Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico.
Reverse Split of Oscient Pharmaceuticals Stock to Be Effected with Market Open November 16, 2006.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters